Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about AstraZeneca PLC
AstraZeneca PLC News
AstraZeneca PLC Quantitative Score
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
AstraZeneca PLC Financials
Table Compare
Compare AZN metrics with: | |||
|---|---|---|---|
Earnings & Growth | AZN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AZN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AZN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AZN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
AstraZeneca PLC Income
AstraZeneca PLC Balance Sheet
AstraZeneca PLC Cash Flow
AstraZeneca PLC Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
AstraZeneca PLC Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 2.9900 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-03-24 | 1.05 | Quarterly |
| 2024-09-09 | 0.49 | Quarterly |
| 2024-03-25 | 0.985 | Quarterly |
| 2023-09-11 | 0.465 | Quarterly |
| 2023-03-27 | 0.965 | Quarterly |
Historical Market Cap
Shares Outstanding
AstraZeneca PLC Executives
| Name | Role |
|---|---|
| Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | Chief Executive Officer & Executive Director |
| Dr. Aradhana Sarin M.D. | Chief Financial Officer & Executive Director |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Haematology R&D |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
| Gonzalo Vina | Head of Global Media Relations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | Chief Executive Officer & Executive Director | Male | 1959 | 7.03M |
| Dr. Aradhana Sarin M.D. | Chief Financial Officer & Executive Director | 1974 | 3.41M | |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Haematology R&D | 1966 | -- | |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit | -- | ||
| Gonzalo Vina | Head of Global Media Relations | -- |